Table 1.
Baseline characteristics of patients for overall survival analysis cohort.
| Histological Type | Pure UC (PUC) |
Variant UC (VUC) |
Neuro- endocrine (NE) |
p value (PUC vs. VUC) |
p value (PUC vs. NE) |
|---|---|---|---|---|---|
| Number of Patients | 286 | 120 | 9 | ||
| Age (mean ± SD) | 69 +/− 11 | 69 +/− 10 | 70 +/− 10 | 0.91 | 0.73 |
| Male | 76% | 71% | 67% | 0.33 | 0.54 |
| Ever Smoker | 65% | 69% | 78% | 0.45 | 0.44 |
| White race | 80% | 82% | 89% | 0.77 | 0.53 |
| Upper Tract Tumors | 14% | 16% | 14% (1 of 7) | 0.74 | 1.00 |
| Cystectomy or (Nephro)ureterectomy | 51% | 60% | 29% (2 of 7) | 0.12 | 0.24 |
| Hgb<10 | 24% | 28% | 22% | 0.45 | 0.88 |
| Liver Metastasis | 20% | 15% | 33% | 0.28 | 0.31 |
| Albumin < 4 g/dL | 66% | 66% | 67% | 0.88 | 0.95 |
| Bellmunt score | 0.42 | 0.03 | |||
| 0 | 15% | 21% | 11% | ||
| 1 | 53% | 45% | 67% | ||
| 2 | 28% | 30% | 0% | ||
| 3 | 4% | 4% | 22% | ||
| ECOG PS | 0.33 | 0.94 | |||
| 0 | 23% | 26% | 22% | ||
| 1 | 50% | 53% | 56% | ||
| 2 | 23% | 21% | 22% | ||
| 3 | 4% | 1% | 0% | ||
| Type of ICI (# patients) | 0.80 | 0.42 | |||
| Atezolizumab | 51% | 50% | 67% | ||
| Avelumab | 1% | 0% | 0% | ||
| Durvalumab | 3% | 5% | 11% | ||
| Nivolumab | 7% | 7% | 11% | ||
| Pembrolizumab | 38% | 38% | 11% |
VUC tumors contain both urothelial plus at least one variant histology. In this cohort, variants included squamous (n=51), micropapillary (n=27), sarcomatoid (n=16), plasmacytoid (n=11), adenocarcinoma (n=9), neuroendocrine (n=9), nested (n=2) and other (n=9).
Characteristics and laboratory data represented for date of ICI initiation. Bellmunt score 0-3 based on number of the following present at time of ICI: Hgb <10, presence of liver metastases, or ECOG PS >0.
Abbreviations: ICI, immune checkpoint inhibitor; Hgb, hemoglobin; ECOG, Eastern Cooperative Oncology Group; PS, performance status; NE, neuroendocrine; PUC, pure urothelial carcinoma; VUC, variant urothelial carcinoma